For decades, adipose tissue was dismissed as passive energy storage, but mounting evidence positions it as a master regulator of systemic aging. A newly identified molecular circuit may explain how fat tissue accelerates whole-body senescence — and why suppressing a single secreted protein could meaningfully extend healthy lifespan.
Published in Aging Cell, the study identifies angiopoietin-like protein 8 (ANGPTL8) — previously associated with lipid metabolism and inflammation — as a direct promoter of adipocyte senescence operating through the AKT2-mTOR-S6K signaling axis. In a large human cohort, circulating ANGPTL8 levels correlated strongly with biological age and all-cause mortality risk, and the protein's inclusion meaningfully improved machine learning models predicting chronological age and survival outcomes. In mice, complete genetic deletion of Angptl8 extended lifespan, preserved physical function with age, and reduced canonical senescence biomarkers specifically within adipose depots. Transcriptomic profiling confirmed age-dependent upregulation of ANGPTL8 in adipocytes alongside activation of pro-senescent gene programs. Mechanistically, ANGPTL8 was shown to physically interact with AKT2 and activate downstream mTOR-S6K phosphorylation, driving cell-autonomous senescence that could be reversed by both genetic knockout and pharmacological mTOR inhibition.
This finding is notable for several reasons beyond its novelty. The mTOR pathway is already a well-established longevity target — rapamycin extends lifespan across multiple model organisms — but most interventions act broadly. Identifying ANGPTL8 as an upstream endocrine trigger that selectively engages AKT2-mTOR in adipocytes suggests a more tissue-targeted intervention strategy with potentially fewer systemic side effects. The integration of human epidemiological data with mouse genetics and cellular mechanistics strengthens causal inference considerably, though mouse lifespan studies rarely translate one-to-one to humans. Key limitations include the observational nature of the human cohort data, absence of interventional human trials, and the possibility that Angptl8 deletion produces compensatory metabolic adaptations confounding longevity outcomes. Still, this work is more than incremental — it positions ANGPTL8 as a plausible therapeutic target and a clinically accessible biomarker for biological aging.
